A study conducted by the liver cancer study group of Japan showed that 4.9 % (10/205) of all ICC patients had a serum AFP level more than 1000 ng/mL, 1 % (2/205) higher than 10,000 ng/mL, and only 0.5 % (1/205) of the ICC patients had a serum AFP level greater than 100,000 ng/mL [1]. The gene discussed is AFP; the disease is intrahepatic cholangiocarcinoma.